When the liver is damaged by chronic diseases, it has the ability to regenerate itself. Cancer, however, can develop during the regeneration process. A team of researchers led by Ludovic Vallier, Einstein Professor for Stem Cells in Regenerative Therapies at the Berlin Institute of Health at Charité (BIH), recently showed that liver regeneration…
In cooperation with the BIH QUEST Center, the Einstein Foundation Berlin honors the Dutch microbiologist Elisabeth Bik, the platform PubPeer, and the initiative PixelQuality with the Einstein Foundation Award for Promoting Quality in Research 2024.
The European Rare Diseases Research Alliance (ERDERA) is holding today, October 28, its official launch event, where it will set out its vision and ambition for tackling rare diseases as part of the EU’s research strategy in this field. Representatives of the European Commission, patients’ organizations and ERDERA project groups will present their…
UNFPA, the United Nations Population Fund, will launch its new “WomenX Collective” programme at the World Health Summit in Berlin on October 14, followed the next day by the opening of its first hub office in a planned global network of centres specializing in the promotion of women's health, especially sexual and reproductive health, in the German…
Prof. Christian Gaebler, an HIV researcher at Charité – Universitätsmedizin Berlin, has a goal: to develop treatments that cure HIV infection in patients or prompt the immune system to keep the virus in check in the long term, even without medications.
A new collaborative study by researchers from the Berlin Institute of Health at Charité (BIH), Queen Mary University of London, University College London, University of Cambridge and the pharmaceutical company GlaxoSmithKline (GSK) shows that proteins measured in a single drop of blood can predict risk for a variety of diseases.
Immunotherapies harness the body’s immune system to fight cancer by influencing the interaction between immune cells and cancer cells. Such treatments have proved successful in combating certain types of cancers like leukemia, but they remain ineffective in some patients and cause resistance. A research group led by Prof. Simon Haas, which is part…
The European Molecular Biology Organization (EMBO) has elected Professor Claudia Langenberg of the Berlin Institute of Health at Charité (BIH), and of the Precision Healthcare University Research Institute (PHURI) at Queen Mary University of London, as a new member. Headquartered in Heidelberg, Germany, EMBO supports talented researchers at all…
Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes back. To be able to intervene faster and on a more targeted basis, researchers at Charité – Universitätsmedizin Berlin, the Berlin Institute of Health at…
